DGI:Opportunistische Infektionen/Kryptokokkose/Weiterführende Literatur und Hilfestellungen: Difference between revisions

From Infektiopedia
imported>Bestem
(Die Seite wurde neu angelegt: „== Weiterführende Literatur und Hilfestellungen == 1) A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of…“)
 
imported>Fuhrmanns
No edit summary
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
== Weiterführende Literatur und Hilfestellungen ==
1) A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management. ''Open Forum Infect Dis. ''2018.


2) British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. ''HIV Med. ''2011.
1. Nelson M, Dockrell D, Edwards S, et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12 Suppl 2:1-140. doi:10.1111/j.1468-1293.2011.00944_1.x


3) WHO-Guidelines for The Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection.
2. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America | Clinical Infectious Diseases | Oxford Academic. Accessed November 7, 2021. <nowiki>https://academic.oup.com/cid/article/50/3/291/392360</nowiki>


4) Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. ''South Afr J HIV Med.''
3. Spec A, Mejia-Chew C, Powderly WG, Cornely OA. EQUAL Cryptococcus Score 2018: A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management. Open Forum Infect Dis. 2018;5(11):ofy299. doi:10.1093/ofid/ofy299


''5) ''Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. ''Clin Infect Dis. ''2010.
4. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Accessed November 7, 2021. <nowiki>https://www.who.int/publications-detail-redirect/9789241550277</nowiki>


''6) ''HIV-associated opportunistic infections of the CNS. ''Lancet Neurol. ''2012.
5. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents. :495.


''7) ''Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
6. Guidelines for the Prevention and Treatment of Opp.pdf. Accessed November 7, 2021. <nowiki>https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</nowiki>
 
7. Tan IL, Smith BR, von Geldern G, Mateen FJ, McArthur JC. HIV-associated opportunistic infections of the CNS. Lancet Neurol. 2012;11(7):605-617. doi:10.1016/S1474-4422(12)70098-4
 
8. Govender NP, Meintjes G, Mangena P, et al. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. South Afr J HIV Med. 2019;20(1):1030. doi:10.4102/sajhivmed.v20i1.1030
 
<br />

Latest revision as of 10:09, 23 November 2021

1. Nelson M, Dockrell D, Edwards S, et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12 Suppl 2:1-140. doi:10.1111/j.1468-1293.2011.00944_1.x

2. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America | Clinical Infectious Diseases | Oxford Academic. Accessed November 7, 2021. https://academic.oup.com/cid/article/50/3/291/392360

3. Spec A, Mejia-Chew C, Powderly WG, Cornely OA. EQUAL Cryptococcus Score 2018: A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management. Open Forum Infect Dis. 2018;5(11):ofy299. doi:10.1093/ofid/ofy299

4. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Accessed November 7, 2021. https://www.who.int/publications-detail-redirect/9789241550277

5. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents. :495.

6. Guidelines for the Prevention and Treatment of Opp.pdf. Accessed November 7, 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf

7. Tan IL, Smith BR, von Geldern G, Mateen FJ, McArthur JC. HIV-associated opportunistic infections of the CNS. Lancet Neurol. 2012;11(7):605-617. doi:10.1016/S1474-4422(12)70098-4

8. Govender NP, Meintjes G, Mangena P, et al. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. South Afr J HIV Med. 2019;20(1):1030. doi:10.4102/sajhivmed.v20i1.1030


Retrieved from "https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Opportunistische_Infektionen/Kryptokokkose/Weiterführende_Literatur_und_Hilfestellungen&oldid=3380"